What is Sava?
Sava is a health-technology enterprise dedicated to democratizing health data through innovative biosensing solutions. By developing technology capable of accessing bodily information just below the skin, the company offers a non-invasive, real-time, and cost-effective alternative to traditional diagnostic methods. This approach addresses a critical gap in the consumer health market, where the demand for actionable, continuous health insights is rapidly increasing. Sava's market position is defined by its commitment to scientific rigor and user-centric design, aiming to empower individuals with the data necessary to make informed wellness decisions. The company operates at the intersection of biotechnology and consumer electronics, targeting a broad demographic that values proactive health management.
How much funding has Sava raised?
Sava has raised a total of $27M across 2 funding rounds:
Angel/Seed
$8M
Series A
$19M
Angel/Seed (2024): $8M with participation from EXOR and Balderton
Series A (2025): $19M led by True Capital, Italian Founders Fund, Balderton, JamJar Investments, Norrsken Vc, Exceptional Ventures, and Athletico Ventures
Key Investors in Sava
True Capital
True Capital Limited is an innovative advisory and investment firm focused on reimagining business through collaboration and support for founders, entrepreneurs, and leaders in the consumer and tech industries.
Italian Founders Fund
Italian Founders Fund is an investment company dedicated to supporting entrepreneurs with Italian roots and global ambitions, investing from Pre-Seed to Series A.
Balderton
Balderton Capital is a London-based venture capital firm that raises dedicated funds to invest in early-stage, high-growth technology companies across Europe.
What's next for Sava?
With the successful closure of its latest funding round, Sava is poised to transition from research and development into a broader commercialization phase. The strategic focus will likely center on scaling manufacturing capabilities, expanding clinical validation studies, and navigating regulatory pathways to bring its biosensing technology to a global audience. As the company continues to build its ecosystem, the emphasis will remain on enhancing the accuracy and accessibility of its health-monitoring tools. Investors are closely watching how Sava integrates its technology into existing digital health infrastructures, which could potentially disrupt traditional diagnostic models and establish a new standard for personal health tracking in the enterprise and consumer sectors.
See full Sava company page
